Bace2 Transgenic Models and Beta-Amyloid Modulation
About the Research Project
Program
Award Type
Standard
Award Amount
$200,000
Active Dates
April 01, 2001 - March 31, 2003
Grant ID
A2001033
Summary
Amyloid beta peptides are created by the activities of beta- and gamma-secretases, two enzymes that are required to cut amyloid precursor protein (APP). Two beta-secretases called BACE1 and BACE2 may be involved in the generation of the toxic amyloid beta proteins. Dr. Wong has bred mice that lack the BACE1 enzyme. He has found that neurons from the mice lacking BACE1 no longer produce amyloid beta peptides, and this suggests that BACE1 is the principal enzyme required to generate amyloid beta proteins. Studies from other laboratories also suggest that BACE2 may serve to limit the production of amyloid beta. To test this hypothesis, Dr. Wong is attempting to create mice that produce high amounts of normal and/or mutant BACE2 to determine if these genetic alterations curtail amyloid beta production in ways that are consistent with the hypothesis. BACE2 mice will also be bred with “AD” mice to determine if the accumulation of amyloid beta is curtailed by the production of high amounts of BACE2. If it is, this knowledge could pave the way for scientists to design and test drugs that increase the level of BACE2 activity in humans with AD.
Grants
Related Grants
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Alzheimer's Disease Research
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD